Efficacy and Safety of IBI-10090 in Ocular Surgery Patients

Phase 2CompletedNCT01606735

ICON Bioscience Inc172 enrolled

Overview

This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

172

Conditions

Inflammation Associated With Cataract Surgery

Interventions

IBI-10090DRUG

dexamethasone

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients scheduled for unilateral cataract surgery Exclusion Criteria: * Ocular, topical, or oral corticosteroids within 7 days of Day 0

Locations (2)

Inland Eye Specialists

Hemet, California, United States

California Eye Professionals

Temecula, California, United States

Outcomes

Primary Outcomes

Anterior Chamber Cell Count at Day 8 Post-Treatment

This study will measure as its primary endpoint the anterior chamber cell count at Day 8 post-treatment. The proportion of patients with anterior chamber cell count = 0 at Day 8 for each dosage group will be compared.

Time frame: 8 days post-treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.